Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.46 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | CCR8 | P51685 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9182724 | 0.90 | SMN1; SMN2 (0.44) | KMT5BKMT5CCCR1CCR5CCR8 | |
| SCHEMBL28995880 | 0.85 | SMN1; SMN2 (0.41) | KMT5BKMT5CCCR1CCR5CCR8 | |
| SCHEMBL6023316 | 0.85 | NR4A2 (0.47) | KMT5BKMT5CCCR1CCR5CCR8 | |
| SCHEMBL6004219 | 0.80 | KMT5B (0.50) | KMT5BKMT5CCCR1NR4A2SOS2 | |
| SCHEMBL862238 | 0.80 | CCR1 (0.50) | CCR1CCR5CCR8SMN1; SMN2TLR8 | |
| SCHEMBL24459981 | 0.79 | NR4A2 (0.38) | KMT5BKMT5CCCR1CCR5CCR8 | |
| SCHEMBL827782 | 0.78 | NR4A2 (0.61) | CCR1CCR5CCR8SMN1; SMN2NR4A2 | |
| SCHEMBL29491409 | 0.78 | NR4A2 (0.61) | CCR1CCR5CCR8SMN1; SMN2NR4A2 | |
| SCHEMBL2710661 | 0.78 | NR4A2 (0.61) | CCR1CCR5CCR8SMN1; SMN2NR4A2 | |
| SCHEMBL5233653 | 0.75 | SMN1; SMN2 (0.49) | CCR1CCR5CCR8SMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SQOR, QSOX1, SQLE | KMT5B 3010/4885KMT5C 2595/4885CCR1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.